These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

632 related items for PubMed ID: 21943360

  • 1. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
    Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL.
    BMC Cancer; 2011 Sep 23; 11():404. PubMed ID: 21943360
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M.
    J Oncol Pharm Pract; 2016 Oct 23; 22(5):702-16. PubMed ID: 26769697
    [Abstract] [Full Text] [Related]

  • 3. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Wang L, Baser O, Kutikova L, Page JH, Barron R.
    Support Care Cancer; 2015 Nov 23; 23(11):3131-40. PubMed ID: 25821144
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G, Lalla A, Barron R, Dubois RW.
    Curr Med Res Opin; 2009 Feb 23; 25(2):401-11. PubMed ID: 19192985
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I, Frutos Pérez-Surio A, Alcácera MA, Andrés R, Salvador MDT.
    Eur J Clin Pharmacol; 2018 Mar 23; 74(3):315-321. PubMed ID: 29152672
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
    De Oliveira Brandao C, Lewis S, Sandschafer D, Crawford J.
    Curr Med Res Opin; 2023 May 23; 39(5):707-718. PubMed ID: 36976784
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
    Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R.
    Value Health; 2011 Jun 23; 14(4):465-74. PubMed ID: 21669371
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party.
    Eur J Cancer; 2006 Oct 23; 42(15):2433-53. PubMed ID: 16750358
    [Abstract] [Full Text] [Related]

  • 16. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R.
    BMC Cancer; 2013 Jan 08; 13():11. PubMed ID: 23298389
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H.
    Oncology; 2006 Jan 08; 70(4):290-3. PubMed ID: 16899982
    [Abstract] [Full Text] [Related]

  • 19. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD007913. PubMed ID: 23076939
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.